Can-Fite BioPharma(CANF) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

XCan-Fite Partner Vetbiolix Accelerate Piclidenoson Development With Clinical Trial For Canine Osteoarthritis
BenzingaMar 20 09:49 ET
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development With Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
GlobeNewswireMar 20 09:45 ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
BenzingaMar 19 13:06 ET
Can-Fite Biopharma Shares Are Trading Lower. The Company Announced a Phase II Design Is Completed and Preparatory Work Is Undergoing for the Initiation of Clinical Study in the Rare Genetic Disease Lowe Syndrome.
BenzingaMar 19 11:38 ET
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome With Piclidenoson
GlobeNewswireMar 19 09:00 ET
Sector Update: Health Care Stocks Edge Down in Afternoon Trading
MT NewswiresMar 18 13:59 ET

Comments

stderr

Mar 21 04:18

$Can-Fite BioPharma (CANF.US)$ How low?

1

151172736

Mar 20 21:54

$Can-Fite BioPharma (CANF.US)$ if you short this that means you hate dogs and people with cancer

2

1

Trytosaveabit

Mar 20 21:54

Update

$Can-Fite BioPharma (CANF.US)$ Can-Fite's upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch
Ramat Gan, Israel, March 20, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it...

1

Teddy123

Mar 20 21:48

Biotech Analysis

$Can-Fite BioPharma (CANF.US)$
Can-Fite's veterinary partnership with Vetbiolix represents a strategic expansion into the $3.8 billion companion animal arthritis market, with Piclidenoson now advancing to an advanced clinical study following successful initial results. The move leverages their existing A3 Adenosine Receptor technology platform into veterinary medicine, where development timelines and approval processes are typically accelerated compared to human therapeutics.
The...

Teddy123

Mar 20 21:46

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

$Can-Fite BioPharma (CANF.US)$
Can-Fite's Breakthrough: New Pet Arthritis Drug Targets Massive $3.8B Market Opportunity

CANF Can-Fite BioPharma

Trade Overview

Capital Trend

News

Comments